Search results
Nektar Therapeutics (NASDAQ:NKTR) Director Sells $23,400.00 in Stock
ETF DAILY NEWS· 7 days agoNektar Therapeutics (NASDAQ:NKTR – Get Free Report) Director Robert Chess sold 19,500 shares of Nektar Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average ...
Lupus Complications Reduced With Common Diabetes Drug
MedPage Today· 3 days agoPeople with systemic lupus erythematosus (SLE) had lower rates of lupus nephritis, chronic kidney disease, and other complications when they were taking ...
Cartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at HC Wainwright
ETF DAILY NEWS· 5 days agoHC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $54.00 ...
CAR-T therapy achieves lupus remission breakthrough
BioPharma-Reporter· 4 days agoThis is the first trial to date to show safe elimination of all autoantibodies in patients with systemic lupus erythematosus (SLE) and lupus nephritis (...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 6 days agoThe biopharmaceutical company, known for its work in developing programmed cell therapies for cancer...
CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory...
Medical Xpress· 2 days agoThis study was led by Professor Junnian Zheng and Ming Shi from the Cancer Institute of Xuzhou Medical University, together with the team of Professor Guiyun Cui and Wei Zhang from the Affiliated ...
Corbus Pharmaceuticals Board Member To Sell Shares In Planned Trading - Corbus Pharmaceuticals...
Benzinga· 5 days agoIn a recent move signaling strategic financial planning, Corbus Pharmaceuticals Holdings, Inc. CRBP...
Hyperkeratosis in Dogs: Symptoms, Causes, & Treatments
Dog Time via AOL· 4 days agoHyperkeratosis in dogs is a condition characterized by the thickening of the skin’s outer layer due...
Citi maintains Buy rating on Cabaletta Bio post-EULAR data By Investing.com
Investing.com· 6 days agoOn Monday, Citi reaffirmed its positive stance on Cabaletta Bio Inc . The endorsement follows the...
Nektar Therapeutics (NASDAQ:NKTR) Share Price Crosses Above Two Hundred Day Moving Average of $0.98
ETF DAILY NEWS· 21 hours agoNektar Therapeutics (NASDAQ:NKTR – Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.98 and traded as high ...